Legal & General Group Plc lifted its stake in shares of Vericel Corp (NASDAQ:VCEL) by 17.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,443 shares of the biotechnology company’s stock after purchasing an additional 943 shares during the quarter. Legal & General Group Plc’s holdings in Vericel were worth $91,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in VCEL. Pacer Advisors Inc. purchased a new position in Vericel in the third quarter worth $112,000. Voya Investment Management LLC purchased a new position in Vericel in the second quarter worth $133,000. Jane Street Group LLC purchased a new position in Vericel in the third quarter worth $239,000. American International Group Inc. raised its position in Vericel by 18.6% in the third quarter. American International Group Inc. now owns 28,505 shares of the biotechnology company’s stock worth $403,000 after acquiring an additional 4,474 shares in the last quarter. Finally, MetLife Investment Advisors LLC raised its position in Vericel by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 28,909 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 10,277 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

In related news, CFO Gerard J. Michel sold 15,625 shares of the stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $16.81, for a total transaction of $262,656.25. Following the transaction, the chief financial officer now directly owns 160,960 shares in the company, valued at $2,705,737.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven C. Gilman sold 8,500 shares of the stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $17.75, for a total value of $150,875.00. Following the transaction, the director now owns 8,500 shares in the company, valued at $150,875. The disclosure for this sale can be found here. Insiders have sold 55,336 shares of company stock worth $941,861 over the last quarter. 4.70% of the stock is currently owned by company insiders.

VCEL has been the subject of several research analyst reports. Oppenheimer initiated coverage on Vericel in a research report on Tuesday, January 29th. They issued an “outperform” rating and a $23.00 price objective for the company. BidaskClub upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. Needham & Company LLC increased their price objective on Vericel to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 6th. Finally, BTIG Research increased their price objective on Vericel from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $18.00.

Vericel stock opened at $17.24 on Monday. The company has a current ratio of 7.96, a quick ratio of 7.71 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $747.30 million, a price-to-earnings ratio of -34.48 and a beta of 2.92. Vericel Corp has a fifty-two week low of $6.50 and a fifty-two week high of $18.87.

WARNING: This report was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2019/02/11/legal-general-group-plc-has-91000-stake-in-vericel-corp-vcel.html.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Recommended Story: Preferred Stock

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.